| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | 低出血抗凝血融合蛋白的制备及其应用 | CN200780046340.6 | 2007-12-11 | CN101668778B | 2012-10-03 | 吴祖泽; 于爱平; 张传领; 唐仲雄 |
| 提供了含有被凝血因子XIa和凝血因子Xa、或凝血酶和凝血因子Xa共同识别并裂解的寡肽的抗凝血融合蛋白。还提供了该抗凝血融合蛋白的制备方法和医药学用途。 | ||||||
| 2 | 因子XI对炎症反应的调节 | CN201080026789.8 | 2010-04-15 | CN102458480A | 2012-05-16 | B·P·莫尼亚; J·R·克罗斯比; R·A·马克雷德; S·M·弗赖尔 |
| 本发明公开了用于在所需个体中调节因子XI和改善炎症疾病、异常或状况的反义化合物和方法。通过给药靶向作用于因子XI的反义化合物，个体所患的炎症疾病如关节炎和结肠炎可以得到改善或预防。 | ||||||
| 3 | 因子11表达的调节 | CN200980150276.5 | 2009-10-15 | CN102245186B | 2014-08-27 | S·M··弗赖尔; B·P··莫尼亚; 张宏; 赵臣广; J·R··克罗斯比; A·M··斯夫科夫斯基 |
| 此处披露了用于在需要的个体中降低因子11以及治疗或预防血栓栓塞性并发症的反义化合物和方法。可以通过将靶向因子11的反义化合物给药而改善的疾病状况的例子包括血栓形成、栓塞以及血栓栓塞，比如如深静脉血栓形成、肺栓塞、心肌梗塞和中风。靶向因子11的反义化合物也可以用作防止个体血栓形成及栓塞风险的预防性治疗。 | ||||||
| 4 | 因子11表达的调节 | CN200980150276.5 | 2009-10-15 | CN102245186A | 2011-11-16 | S·M.·弗赖尔; B·P.·莫尼亚; 张宏; 赵臣广; J·R.·克罗斯比; A·M.·斯夫科夫斯基 |
| 此处披露了用于在需要的个体中降低因子11以及治疗或预防血栓栓塞性并发症的反义化合物和方法。可以通过将靶向因子11的反义化合物给药而改善的疾病状况的例子包括血栓形成、栓塞以及血栓栓塞，比如如深静脉血栓形成、肺栓塞、心肌梗塞和中风。靶向因子11的反义化合物也可以用作防止个体血栓形成及栓塞风险的预防性治疗。 | ||||||
| 5 | 蛋白质的体内产生 | CN201380028186.5 | 2013-03-15 | CN104870022A | 2015-08-26 | 斯蒂芬·邦塞尔; 提尔塔·柴可拉博提; 安东宁·德富热罗勒; S·M·伊巴希尔; 马蒂亚斯·约翰; 阿坦恩·洛依; 苏珊·沃利斯基; K·M·伍德; 保罗·哈塔拉; 杰森·P·斯洛姆; 凯内齐·伊杰贝; 杰夫·L·埃尔斯沃思; 贾斯汀·基尔德 |
| 本发明涉及用于多核苷酸、初级转录物和mmRNA分子的制备、制造和治疗用途的组合物和方法。 | ||||||
| 6 | 低出血抗凝血融合蛋白的制备及其应用 | CN200780046340.6 | 2007-12-11 | CN101668778A | 2010-03-10 | 吴祖泽; 于爱平; 张传领; 唐仲雄 |
| 提供了含有被凝血因子XIa和凝血因子Xa、或凝血酶和凝血因子Xa共同识别并裂解的寡肽的抗凝血融合蛋白。还提供了该抗凝血融合蛋白的制备方法和医药学用途。 | ||||||
| 7 | 인자 １１ 발현의 조정 | KR1020117010915 | 2009-10-15 | KR1020110081294A | 2011-07-13 | 프라이어,수잔,엠.; 모니아,브렛,피.; 장,훙; 자오,천광; 크로스비,제프리,알.; 시우코우스키,앤드류,엠. |
| 필요로 하는 개체에서 인자 11을 감소시키고 혈전색전성 합병증을 치료 또는 예방하기 위한 안티센스 화합물 및 방법이 본원에 개시된다. 인자 11을 표적으로 하는 안티센스 화합물의 투여로 개선될 수 있는 질환 상태의 예로는 혈전증, 색전증, 및 혈전색전증, 예컨대 심부 정맥 혈전증, 폐 색전증, 심근 경색증, 및 졸중이 포함된다. 인자 11을 표적으로 하는 안티센스 화합물은 혈전증 및 색전증의 위험이 있는 개체를 예방하기 위한 예방적 처치로서 또한 사용될 수 있다. | ||||||
| 8 | 인자 ＸＩ의 치료적 사용 | KR1020067009406 | 2004-11-22 | KR1020060118486A | 2006-11-23 | 뢰이크자에르라스무스; 비우프도르테; 외스테르가르드쇠렌; 젠센시몬베레가르드; 한센젠스자콥 |
| The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced clotting time; enhancement of hemostasis; increase in clot lysis time; increase in clot strength; and/or increase in overall clot quality (OCQ) in said patient. | ||||||
| 9 | 인자 １１ 발현의 조정 | KR1020177023938 | 2009-10-15 | KR1020170101324A | 2017-09-05 | 프라이어,수잔,엠.; 모니아,브렛,피.; 장,훙; 자오,천광; 크로스비,제프리,알.; 시우코우스키,앤드류,엠. |
| 필요로하는개체에서인자 11을감소시키고혈전색전성합병증을치료또는예방하기위한안티센스화합물및 방법이본원에개시된다. 인자 11을표적으로하는안티센스화합물의투여로개선될수 있는질환상태의예로는혈전증, 색전증, 및혈전색전증, 예컨대심부정맥혈전증, 폐색전증, 심근경색증, 및졸중이포함된다. 인자 11을표적으로하는안티센스화합물은혈전증및 색전증의위험이있는개체를예방하기위한예방적처치로서또한사용될수 있다. | ||||||
| 10 | 인자 １１ 발현의 조정 | KR1020117010915 | 2009-10-15 | KR101773551B1 | 2017-08-31 | 프라이어,수잔,엠.; 모니아,브렛,피.; 장,훙; 자오,천광; 크로스비,제프리,알.; 시우코우스키,앤드류,엠. |
| 필요로하는개체에서인자 11을감소시키고혈전색전성합병증을치료또는예방하기위한안티센스화합물및 방법이본원에개시된다. 인자 11을표적으로하는안티센스화합물의투여로개선될수 있는질환상태의예로는혈전증, 색전증, 및혈전색전증, 예컨대심부정맥혈전증, 폐색전증, 심근경색증, 및졸중이포함된다. 인자 11을표적으로하는안티센스화합물은혈전증및 색전증의위험이있는개체를예방하기위한예방적처치로서또한사용될수 있다. | ||||||
| 11 | Modified polynucleotides for the production of biologics and proteins associated with human disease | US14878400 | 2015-10-08 | US09814760B2 | 2017-11-14 | Stephane Bancel; Tirtha Chakraborty; Antonin de Fougerolles; Sayda M. Elbashir; Matthias John; Atanu Roy; Susan Whoriskey; Kristy M. Wood; Paul Hatala; Jason P. Schrum; Kenechi Ejebe; Jeff Lynn Ellsworth; Justin Guild |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 12 | FACTOR XIA-SPECIFIC APTAMERS | US15586581 | 2017-05-04 | US20170321218A1 | 2017-11-09 | William Peter Sheffield; David Apraku Donkor |
| The present disclosure concerns aptamers of formula (I) capable of specifically binding to Factor XIa. The aptamers can be used to prevent, treat or alleviate the symptoms of thrombosis. The aptamers can also be used to detect Factor XIa in a sample and/or purify Factor XIa from a sample. The aptamers can further be used to identity putative therapeutic agents for the prevention, treatment or alleviation of symptoms associated with thrombosis. | ||||||
| 13 | MODULATION OF FACTOR 11 EXPRESSION | US15075545 | 2016-03-21 | US20170035798A1 | 2017-02-09 | Susan M. Freier; Chenguang Zhao; Brett P. Monia; Hong Zhang; Jeffrey R. Crosby; Andrew M. Siwkowski |
| Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism. | ||||||
| 14 | METHOD FOR PREPARING A CONCENTRATE OF FACTOR XI | US14873549 | 2015-10-02 | US20160024488A1 | 2016-01-28 | Jean-Francois Martin |
| The invention concerns a concentrate of human Factor XI having high specific activity prepared using a method comprising a filtration-adsorption step and a chromatography step on cation exchange resin. The concentrate obtained is fully adapted for therapeutic use as substitution therapy in cases of Factor XI deficiency. | ||||||
| 15 | Modified polynucleotides encoding citeD4 | US14104556 | 2013-12-12 | US09114113B2 | 2015-08-25 | Tirtha Chakraborty; Antonin de Fougerolles |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 16 | Modified polynucleotides for treating galactosylceramidase protein deficiency | US14171249 | 2014-02-03 | US09089604B2 | 2015-07-28 | Tirtha Chakraborty; Antonin de Fougerolles; Ron Weiss |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 17 | MODIFIED POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | US14170747 | 2014-02-03 | US20140194494A1 | 2014-07-10 | Stephane Bancel; Tirtha Chakraborty; Antonin de Fougerolles; Susan Whoriskey |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 18 | MODIFIED POLYNUCLEOTIDES ENCODING V-MYC AVIAN MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG | US14104585 | 2013-12-12 | US20140193482A1 | 2014-07-10 | Stephane Bancel; Tirtha Chakraborty; Antonin de Fougerolles; Susan Whoriskey; Ron Weiss |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 19 | MODIFIED POLYNUCLEOTIDES FOR TREATING CYSTIC FIBROSIS | US14170910 | 2014-02-03 | US20140155474A1 | 2014-06-05 | Stephane Bancel; Tirtha Chakraborty; Antonin de Fougerolles; Susan Whoriskey |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
| 20 | MODIFIED POLYNUCLEOTIDES ENCODING HEPATITIS A VIRUS CELLULAR RECEPTOR 2 | US14105208 | 2013-12-13 | US20140105966A1 | 2014-04-17 | Stephane Bancel; Tirtha Chakraborty; Antonin de Fougerolles; Susan Whoriskey; Ron Weiss |
| The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | ||||||
QQ群二维码
意见反馈
意见反馈